Latest quarterly results from Swiss companies

Syngenta and Serono have both announced declining results Keystone Archive

Swiss companies have announced their quarterly earnings with declining results in the chemical industry.

This content was published on April 24, 2002 - 10:27

The Basel-based agri-chemical giant Syngenta has reported a decline in its first quarter sales of three per cent, which is worse than analysts expected.

The company's first quarter sales were SFr3.05 billion ($1.84 billion) down from SFr3.15 billion a year ago, with sales in crop protection also down three per cent. That comes in the context of a depressed global agriculture market.

Analysts had expected sales to drop by 1.5 per cent as distributors continued to run down their stocks and the currency in Latin America got weaker.

"First quarter performance indicates that barring further unfavourable currency movements, synergy realisation will result in some marginal improvement in 2002," the company said in a statement.


Serono, Europe's biggest biotechnology company, has announced a first quarter net profit of SFr115.3 million, a 3.5 per cent decrease.

However, the Geneva-based company is sticking by its forecast of full-year earnings growth of 15 to 17 per cent.

Total product sales rose by 10.4 per cent to SFr519 million with sales of Serono's multiple sclerosis drug Rebif, which was launched in the United States last month, rising 45.7 per cent to SFr191 million.


The bathroom fixtures company Geberit Holding has reported a 2.1 per cent increase in sales to SFr331 million, up from SFr324.3 million last year.

The Jona-based company said in a statement it expected a similar development for the whole year.

swissinfo with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know:

Comments under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Join the conversation!

With a SWI account, you have the opportunity to contribute on our website.

You can Login or register here.